Preclinical modeling of EGFR inhibitor resistance in head and neck cancer

Cancer Biology and Therapy

Volumn 13, Issue 10, 2012, Pages 935-945

  Quesnelle, Kelly M ^a   Wheeler, Sarah E ^a   Ratay, Mary K ^a   Grandis, Jennifer R ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Cetuximab; Cetuximab resistance; Epidermal growth factor receptor (EGFR); Erlotinib; Erlotinib resistance; Heterotopic tumorgraft; HNSCC; Xenograft

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB;

ARTICLE; CANCER GRAFT; CANCER RESISTANCE; CHEMOSENSITIVITY; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG RESPONSE; DRUG SENSITIZATION; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; PROTEIN EXPRESSION; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; HEAD AND NECK NEOPLASMS; HUMANS; INHIBITORY CONCENTRATION 50; MICE; MICE, NUDE; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84864542307     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.20846     Document Type: Article

References (46)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics. CA Cancer J Clin 2008; 58:71-96; PMID:18287387; http://dx.doi.org/ 10.3322/CA.2007.0010.
2. Hunter KD, Parkinson EK, Harrison PR. Profiling early head and neck cancer. Nat Rev Cancer 2005; 5:127-35; PMID:15685196; http://dx.doi.org/10.1038/ nrc1549.
3. Marur S, Forastiere AA. Head and neck cancer: changing epidemiology, diagnosis and treatment. Mayo Clin Proc 2008; 83:489-501; PMID:18380996; http://dx.doi.org/10.4065/83.4.489.
4. Mrhalova M, Plzak J, Betka J, Kodet R. Epidermal growth factor receptor - its expression and copy numbers of EGFR gene in patients with head and neck squamous cell carcinomas. Neoplasma 2005; 52:338-43; PMID:16059652.
5. Grandis JR, Tweardy DJ. Elevated levels of transforming growth factoralpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 1993; 53:3579-84; PMID:8339264.
6. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359:1116-27; PMID:18784101; http://dx.doi.org/10.1056/NEJMoa0802656.
7. Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Siu LL. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004; 22:77-85; PMID:14701768; http://dx.doi.org/10.1200/JCO.2004.06.075.
8. Vermorken JB, Trigo J, Hitt R, Koralewski P, Diaz-Rubio E, Rolland F, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007; 25:2171-7; PMID:17538161; http://dx.doi.org/10.1200/JCO.2006.06.7447.
9. Viloria-Petit A, Crombet T, Jothy S, Hicklin D, Bohlen P, Schlaeppi JM, et al. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res 2001; 61:5090-101; PMID:11431346.
10. Niu G, Sun X, Cao Q, Courter D, Koong A, Le QT, et al. Cetuximab-based immunotherapy and radioimmunotherapy of head and neck squamous cell carcinoma. Clin Cancer Res 2010; 16:2095-105; PMID:20215534; http://dx.doi.org/10.1158/ 1078-0432.CCR-09-2495.
11. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecanrefractory metastatic colorectal cancer. N Engl J Med 2004; 351:337-45; PMID:15269313; http://dx.doi.org/10.1056/NEJMoa033025.
12. Quesnelle KM, Grandis JR. Dual kinase inhibition of EGFR and HER2 overcomes resistance to cetuximab in a novel in vivo model of acquired cetuximab resistance. Clin Cancer Res 2011; 17:5935-44; PMID:21791633; http://dx.doi.org/10.1158/1078-0432.CCR-11-0370.
13. Ciardiello F, Bianco R, Caputo R, Caputo R, Damiano V, Troiani T, et al. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Clin Cancer Res 2004; 10:784-93; PMID:14760102; http://dx.doi.org/10.1158/1078-0432.CCR-1100-03.
14. Paranavitana CM. Non-radioactive detection of K-ras mutations by nested allele specific PCR and oligonucleotide hybridization. Mol Cell Probes 1998; 12:309-15; PMID:9778456; http://dx.doi.org/10.1006/mcpr.1998.0185.
15. Seiwert TY, Jagadeeswaran R, Faoro L, Janamanchi V, Nallasura V, El Dinali M, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res 2009; 69:3021-31; PMID:19318576; http://dx.doi.org/10.1158/0008-5472.CAN-08-2881.
16. Benavente S, Huang S, Armstrong EA, Chi A, Hsu KT, Wheeler DL, et al. Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells. Clin Cancer Res 2009; 15:1585-92; PMID:19190133; http://dx.doi.org/10.1158/1078-0432. CCR-08-2068.
17. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361:947-57; PMID:19692680; http://dx.doi.org/10.1056/NEJMoa0810699.
18. Yamasaki F, Zhang D, Bartholomeusz C, Sudo T, Hortobagyi GN, Kurisu K, et al. Sensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activity. Mol Cancer Ther 2007; 6:2168-77; PMID:17671085; http://dx.doi.org/10.1158/1535-7163.MCT-06-0514.
19. Yao Z, Fenoglio S, Gao DC, Camiolo M, Stiles B, Lindsted T, et al. TGFbeta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer. Proc Natl Acad Sci USA 2010; 107:15535-40; PMID:20713723; http://dx.doi.org/10.1073/pnas.1009472107.
20. Muller S, Su L, Tighiouart M, Saba N, Zhang H, Shin DM, et al. Distinctive E-cadherin and epidermal growth factor receptor expression in metastatic and nonmetastatic head and neck squamous cell carcinoma: predictive and prognostic correlation. Cancer 2008; 113:97-107; PMID:18473353; http://dx.doi.org/10.1002/cncr.23557.
21. Haddad Y, Choi W, McConkey DJ. Delta-crystallin enhancer binding factor 1 controls the epithelial to mesenchymal transition phenotype and resistance to the epidermal growth factor receptor inhibitor erlotinib in human head and neck squamous cell carcinoma lines. Clin Cancer Res 2009; 15:532-42; PMID:19147758; http://dx.doi.org/10.1158/1078-0432.CCR-08-1733.
22. Hirsch FR, Varella-Garcia M, McCoy J, West H, Xavier AC, Gumerlock P, et al.; Southwest Oncology Group. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. J Clin Oncol 2005; 23:6838-45; PMID:15998906; http://dx.doi.org/10.1200/JCO.2005.01.2823.
23. Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005; 97:643-55; PMID:15870435; http://dx.doi.org/10.1093/jnci/dji112.
24. Cappuzzo F, Ligorio C, Jänne PA, Toschi L, Rossi E, Trisolini R, et al. Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial. J Clin Oncol 2007; 25:2248-55; PMID:17538169; http://dx.doi.org/10.1200/JCO.2006.09. 4300.
25. Sequist LV, Bell DW, Lynch TJ, Haber DA. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol 2007; 25:587-95; PMID:17290067; http://dx.doi.org/10.1200/JCO.2006. 07.3585.
26. Agulnik M, da Cunha Santos G, Hedley D, Nicklee T, Dos Reis PP, Ho J, et al. Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib. J Clin Oncol 2007; 25:2184-90; PMID:17538163; http://dx.doi.org/10.1200/JCO.2006.07.6554.
27. Lin CJ, Grandis JR, Carey TE, Gollin SM, Whiteside TL, Koch WM, et al. Head and neck squamous cell carcinoma cell lines: established models and rationale for selection. Head Neck 2007; 29:163-88; PMID:17312569; http://dx.doi.org/10.1002/hed.20478.
28. Wheeler DLHS, Huang S, Kruser TJ, Nechrebecki MM, Armstrong EA, Benavente S, et al. Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene 2008; 27:3944-56; PMID:18297114; http://dx.doi.org/10. 1038/onc.2008.19.
29. Ritter CA, Perez-Torres M, Rinehart C, Guix M, Dugger T, Engelman JA, et al. Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin Cancer Res 2007; 13:4909-19; PMID:17699871; http://dx.doi.org/10.1158/1078-0432.CCR-07-0701.
30. Studer G, Lütolf UM, El-Bassiouni M, Rousson V, Glanzmann C. Volumetric staging (VS) is superior to TNM and AJCC staging in predicting outcome of head and neck cancer treated with IMRT. Acta Oncol 2007; 46:386-94; PMID:17450476; http://dx.doi.org/10.1080/02841860600815407.
31. Garber K. From human to mouse and back: 'tumor-graft' models surge in popularity. J Natl Cancer Inst 2009; 101:6-8; PMID:19116380; http://dx.doi.org/10.1093/jnci/djn481.
32. Hidalgo M, Bruckheimer E, Rajeshkumar NV, Garrido-Laguna I, De Oliveira E, Rubio-Viqueira B, et al. A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol Cancer Ther 2011; 10:1311-6; PMID:21673092; http://dx.doi.org/10.1158/1535-7163.MCT-11-0233.
33. Morelli MP, Calvo E, Ordonez E, Wick MJ, Viqueira BR, Lopez-Casas PP, et al. Prioritizing Phase I Treatment Options Through Preclinical Testing on Personalized Tumorgraft. J Clin Oncol 2011; PMID:22184402.
34. Hamilton M, Wolf JL, Rusk J, Beard SE, Clark GM, Witt K, et al. Effects of smoking on the pharmacokinetics of erlotinib. Clin Cancer Res 2006; 12:2166-71; PMID:16609030; http://dx.doi.org/10.1158/1078-0432.CCR-05-2235.
35. Memon AA, Jakobsen S, Dagnaes-Hansen F, Sorensen BS, Keiding S, Nexo E. Positron emission tomography (PET) imaging with [11C]-labeled erlotinib: a micro-PET study on mice with lung tumor xenografts. Cancer Res 2009; 69:873-8; PMID:19155297; http://dx.doi.org/10.1158/0008-5472.CAN-08-3118.
36. Petty WJ, Dragnev KH, Memoli VA, Ma Y, Desai NB, Biddle A, et al. Epidermal growth factor receptor tyrosine kinase inhibition represses cyclin D1 in aerodigestive tract cancers. Clin Cancer Res 2004; 10:7547-54; PMID:15569985; http://dx.doi.org/10.1158/1078-0432.CCR-04-1169.
37. Zhao M, Sano D, Pickering CR, Jasser SA, Henderson YC, Clayman GL, et al. Assembly and initial characterization of a panel of 85 genomically validated cell lines from diverse head and neck tumor sites. Clin Cancer Res 2011; 17:7248-64; PMID:21868764; http://dx.doi.org/10.1158/1078-0432.CCR-11-0690.
38. Pirker R, Pereira JR, von Pawel J, Krzakowski M, Ramlau R, Park K, et al. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol 2012; 13:33-42; PMID:22056021; http://dx.doi.org/10.1016/S1470-2045(11)70318-7.
39. López-Albaitero A, Lee SC, Morgan S, Grandis JR, Gooding WE, Ferrone S, et al. Role of polymorphic Fcgamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells. Cancer Immunol Immunother 2009; 58:1853-64; PMID:19319529; http://dx.doi.org/10.1007/s00262-009-0697-4.
40. Huang WC, Chen YJ, Li LY, Wei YL, Hsu SC, Tsai SL, et al. Nuclear translocation of epidermal growth factor receptor by Akt-dependent phosphorylation enhances breast cancer-resistant protein expression in gefitinib-resistant cells. J Biol Chem 2011; 286:20558-68; PMID:21487020; http://dx.doi.org/10.1074/jbc.M111.240796.
41. Li C, Iida M, Dunn EF, Ghia AJ, Wheeler DL. Nuclear EGFR contributes to acquired resistance to cetuximab. Oncogene 2009; 28:3801-13; PMID:19684613; http://dx.doi.org/10.1038/onc.2009.234.
42. Thomas JM. A lung colony clonogenic cell assay for human malignant melanoma in immune-suppressed mice and its use to determine chemosensitivity, radiosensitivity and the relationship between tumour size and response to therapy. Br J Surg 1979; 66:696-700; PMID:509043; http://dx.doi.org/10.1002/bjs. 1800661007.
43. Zhu S, Belkhiri A, El-Rifai W. DARPP-32 increases interactions between epidermal growth factor receptor and ERBB3 to promote tumor resistance to gefitinib. Gastroenterology 2011; 141:1738-48.
44. Bubeník J, Baresová M, Viklický V, Jakoubková J, Sainerová H, Donner J. Established cell line of urinary bladder carcinoma (T24) containing tumour-specific antigen. Int J Cancer 1973; 11:765-73; PMID:4133950; http://dx.doi.org/10.1002/ijc.2910110327.
45. Linsley PS, Fox CF. Direct linkage of EGF to its receptor: characterization and biological relevance. J Supramol Struct 1980; 14:441-59; PMID:6264232; http://dx.doi.org/10.1002/jss.400140404.
46. Scherer WF, Syverton JT, Gey GO. Studies on the propagation in vitro of poliomyelitis viruses. IV. Viral multiplication in a stable strain of human malignant epithelial cells (strain HeLa) derived from an epidermoid carcinoma of the cervix. J Exp Med 1953; 97:695-710; PMID:13052828; http://dx.doi.org/10. 1084/jem.97.5.695.